🔗 Share this article

While the US undertakes sweeping changes to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on COVID-19 shots in the pandemic and has focused upon possible deaths after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Agency leaders were set to unveil radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s immunization schedule, sources say – a major change that would put the US at odds with many the international standard with little proof for benefit. The announcement has been delayed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has frequently advocated for halting some childhood vaccine recommendations in the US so as to align more in line with Denmark, a nation with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Qualifications

The appointee has little discernible experience in drug development, approval processes or leadership, which has been typical for past heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Former heads of the center would “grasp laws and regulations and the science of medication creation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that previous people who ran CBER have had.”

The drug center has an vast portfolio at the agency, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic program authorizes thousands of generic medications. There is also a biosimilars division, OTC medication office and more, and all of those have to be looked after,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the role, which manages over 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” the former official concluded.

Response and Contentious Initiatives

In response to inquiries about Høeg’s credentials and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a representative said that the “questions stem from incorrect premises”.

“Her resume aligns with the functions of her role,” the representative said, citing the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial expedited review system, a controversial rapid therapy clearance system that apparently concerned her former heads. “By what process are these drugs being selected for this expedited pathway? Who is making the calls?” Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards laxer regulations of most medications, with the exception of vaccines.”

Public History on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, track record, critics have noted. She authored a analysis using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new administration included altering regulations for novel immunizations and discontinuing “unnecessary” vaccines, she remarked following the vote on a online show. At the agency, Høeg has allegedly suggested excluding teenage boys from getting COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her preconceived notions and works backwards to retrofit the science in a highly disingenuous, untruthful way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|